Tenaya Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Tenaya Therapeutics
TNYA Stock  USD 2.04  0.11  5.12%   
Tenaya Therapeutics financial statements provide useful quarterly and yearly information to potential Tenaya Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Tenaya Therapeutics financial statements helps investors assess Tenaya Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Tenaya Therapeutics' valuation are summarized below:
Market Capitalization
160.9 M
Earnings Share
(1.53)
We have found one hundred twenty available fundamental trend indicators for Tenaya Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Tenaya Therapeutics current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of October 20, 2024, Market Cap is expected to decline to about 227.1 M. In addition to that, Enterprise Value is expected to decline to about 195.5 M
Check Tenaya Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenaya Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 7 M or Interest Income of 7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.8. Tenaya financial statements analysis is a perfect complement when working with Tenaya Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tenaya Therapeutics Correlation against competitors.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.

Tenaya Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets209 M170.5 M100.1 M
Slightly volatile
Other Current Liabilities6.9 M12.8 M4.6 M
Slightly volatile
Total Current Liabilities17.1 M22.7 M8.8 M
Slightly volatile
Other Liabilities194.9 K205.2 K3.4 M
Slightly volatile
Property Plant And Equipment Net43.4 M53.3 M21.8 M
Slightly volatile
Accounts Payable6.1 M5.6 M2.6 M
Slightly volatile
Cash72.9 M45.7 M41.3 M
Slightly volatile
Non Current Assets Total50.9 M58.9 M25 M
Slightly volatile
Non Currrent Assets Other3.2 M5 M1.3 M
Slightly volatile
Other Assets0.951.01.1 M
Slightly volatile
Cash And Short Term Investments157.4 M104.6 M74.2 M
Slightly volatile
Common Stock Shares Outstanding53.3 M73.8 M44.4 M
Slightly volatile
Liabilities And Stockholders Equity209 M170.5 M100.1 M
Slightly volatile
Non Current Liabilities Total7.9 M8.4 M69.5 M
Slightly volatile
Other Current Assets4.6 M6.9 M2.4 M
Slightly volatile
Other Stockholder Equity569.9 M542.8 M117.6 M
Slightly volatile
Total Liabilities29.5 M31.1 M94.8 M
Pretty Stable
Property Plant And Equipment Gross52.2 M77.6 M25.1 M
Slightly volatile
Total Current Assets158 M111.6 M75.1 M
Slightly volatile
Non Current Liabilities Other240.3 K253 K1.8 M
Slightly volatile
Net Working Capital140.9 M88.8 M66.3 M
Slightly volatile
Common Stock4.4 K8.1 K2.3 K
Slightly volatile
Property Plant Equipment33.2 M58.7 M19.9 M
Slightly volatile
Short and Long Term Debt Total11 M12.4 M13.5 M
Slightly volatile
Current Deferred Revenue7.1 M8 M8.7 M
Slightly volatile
Common Stock Total Equity6 K8.1 K4.6 K
Slightly volatile
Capital Surpluse526.4 M601.4 M457.4 M
Slightly volatile
Short Term Debt3.8 M4.3 M2.4 M
Slightly volatile
Net Receivables1.8 M2 M2.2 M
Slightly volatile

Tenaya Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income7 M6.6 M1.4 M
Slightly volatile
Interest Income7 M6.6 M1.4 M
Slightly volatile
Depreciation And Amortization5 M8.7 M3 M
Slightly volatile
Selling General Administrative20.9 M33.2 M10.5 M
Slightly volatile
Other Operating Expenses87.2 M131.2 M48.9 M
Slightly volatile
Research Development66.3 M98 M38.4 M
Slightly volatile
Cost Of Revenue5.7 M8.7 M3.3 M
Slightly volatile
Total Operating Expenses85.3 M122.5 M48.1 M
Slightly volatile
Reconciled Depreciation5 M8.6 M3 M
Slightly volatile
Total Other Income Expense Net7.5 M7.1 M2.1 M
Slightly volatile
Non Operating Income Net Other2.4 M2.2 M505.8 K
Slightly volatile
Selling And Marketing Expenses6.9 M7.8 M8.5 M
Slightly volatile

Tenaya Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation16.1 M15.3 M3.4 M
Slightly volatile
Begin Period Cash Flow68.4 M95.3 M39.3 M
Slightly volatile
Depreciation5 M8.7 M3 M
Slightly volatile
Capital Expenditures1.2 M1.2 M5.8 M
Slightly volatile
Issuance Of Capital Stock119.9 M81.3 M62.6 M
Slightly volatile
Total Cash From Financing Activities3.8 M4 M49.8 M
Pretty Stable
End Period Cash Flow73.3 M45.7 M41.7 M
Slightly volatile
Other Cashflows From Investing Activities6.4 K7.2 K7.8 K
Slightly volatile
Change To Netincome14.1 M13.4 M3.1 M
Slightly volatile
Change To Liabilities5.1 M6.9 M2.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.140.14262.04
Pretty Stable
Payables Turnover1.891.5432.6873
Slightly volatile
Cash Per Share2.471.41821.5824
Slightly volatile
Interest Coverage51.4 K57.8 K62.9 K
Slightly volatile
Days Payables Outstanding299237211
Slightly volatile
Income Quality0.960.82260.9048
Slightly volatile
Net Debt To EBITDA0.260.27150.9543
Very volatile
Current Ratio4.664.90848.1602
Pretty Stable
Graham Number8.58.45566.4322
Slightly volatile
Debt To Equity0.05540.08910.0589
Slightly volatile
Capex Per Share0.0160.01680.1367
Slightly volatile
Interest Debt Per Share0.330.16840.3599
Slightly volatile
Debt To Assets0.04720.07290.0516
Slightly volatile
Days Of Payables Outstanding299237211
Slightly volatile
Ebt Per Ebit1.070.94580.9634
Slightly volatile
Long Term Debt To Capitalization0.03880.05490.0467
Pretty Stable
Total Debt To Capitalization0.05160.08180.0555
Slightly volatile
Debt Equity Ratio0.05540.08910.0589
Slightly volatile
Quick Ratio4.664.90848.215
Pretty Stable
Net Income Per E B T0.780.90.9642
Slightly volatile
Cash Ratio1.912.00956.2026
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.321.01211.1622
Slightly volatile
Debt Ratio0.04720.07290.0516
Slightly volatile

Tenaya Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap227.1 M239.1 M552.2 M
Slightly volatile
Enterprise Value195.5 M205.8 M516.4 M
Slightly volatile

Tenaya Fundamental Market Drivers

Cash And Short Term Investments104.6 M

Tenaya Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tenaya Therapeutics Financial Statements

Tenaya Therapeutics stakeholders use historical fundamental indicators, such as Tenaya Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Tenaya Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Tenaya Therapeutics' assets and liabilities are reflected in the revenues and expenses on Tenaya Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Tenaya Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue8 M7.1 M
Cost Of Revenue8.7 M5.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
MSFTMicrosoft
FFord Motor
CRMSalesforce
When determining whether Tenaya Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenaya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenaya Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenaya Therapeutics Stock:
How To Invest In Tenaya
Details
Is Tenaya Stock a good investment?
Details
What is Tenaya Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Tenaya Therapeutics Correlation against competitors.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.53)
Return On Assets
(0.41)
Return On Equity
(0.75)
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY